Mutant KRAS Inhibitor (Mirati Therapeutics)

Mutant KRAS Inhibitor (Mirati Therapeutics) refers to a discovery-stage research program focused on the development of small molecule inhibitors targeting oncogenic mutations of the KRAS protein. Developed by Mirati Therapeutics (now a subsidiary of Bristol Myers Squibb), this program is currently in the lead optimization phase. It aims to expand the company's portfolio of KRAS-targeted therapies beyond its lead candidates, such as the G12C-selective inhibitor adagrasib and the G12D-selective inhibitor MRTX1133. The program targets various solid tumors where KRAS mutations drive tumor growth and survival, utilizing small molecules to bind and inhibit the mutant GTPase, thereby disrupting downstream signaling pathways like MAPK/ERK and PI3K/AKT.

Other names

Mutant KRAS Inhibitor (Discovery)